ATH-1017 Market

“ATH-1017 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about ATH-1017 for Alzheimer’s disease in Japan. A detailed picture of the ATH-1017 for Alzheimer’s disease in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the ATH-1017 for Alzheimer’s disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ATH-1017 market forecast analysis for Alzheimer’s disease in Japan, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Alzheimer’s disease.

Drug Summary

Fosgonimeton (ATH-1017) is a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue. The function of the HGF/MET receptor system may be impaired in the brain under conditions of neurodegeneration. HGF is a potent neurotrophic factor active in many cell types of the CNS. HGF activity, through the receptor tyrosine kinase MET, promotes survival and regeneration in various neuron types, including hippocampal, midbrain dopaminergic, cortical, motor, sensory, and cerebellar granular neurons. HGF signaling is also active in glial cells. Activation of the HGF/MET system induces a variety of proneuronal and procognitive processes, and the neurophysiological effects of HGF are well-suited to promote neuronal survival and potentially address the neurodegenerative cascade observed in Alzheimer’s disease and other types of dementia.

The drug has completed a Phase II study and is undergoing two Phase II/III clinical trials. It expects to complete enrollment of Phase II/III LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients by the first quarter of 2024, with topline data expected in the second half of 2024. In addition to Alzheimer’s disease, fosgonimeton can potentially address the broader dementia population, including Parkinson’s disease dementia and dementia with Lewy bodies, as the mode of action focuses on network recovery and synaptic signal transmission in the brain.

Gain a deeper understanding of the Market with DelveInsight’s detailed report @ Alzheimer’s Disease Treatment Market Size

Scope of the Report 

The report provides insights into:

• A comprehensive product overview including the ATH-1017 description, mechanism of action, dosage and administration, research and development activities in Alzheimer’s disease.
• Elaborated details on ATH-1017 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ATH-1017 research and development activities in Alzheimer’s disease across Japan.
• The report also covers the patents information with expiry timeline around ATH-1017.
• The report contains forecasted sales of ATH-1017 for Alzheimer’s disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Alzheimer’s disease.
• The report also features the SWOT analysis with analyst views for ATH-1017 in Alzheimer’s disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Unlock comprehensive insights! Click Here to Purchase the Full Epidemiology Report @ Alzheimer’s Disease Prevalence

ATH-1017 Analytical Perspective by DelveInsight

• In-depth ATH-1017 Market Assessment

This report provides a detailed market assessment of ATH-1017 for Alzheimer’s disease in Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

• ATH-1017 Clinical Assessment

The report provides the clinical trials information of ATH-1017 for Alzheimer’s disease covering trial interventions, trial conditions, trial status, start and completion dates.

Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Alzheimer’s Disease Treatment Drugs

Report Highlights  

• In the coming years, the market scenario for Alzheimer’s disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ATH-1017 dominance.
• Other emerging products for Alzheimer’s disease are expected to give tough market competition to ATH-1017 and launch of late-stage emerging therapies in the near future will significantly impact the market. 
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ATH-1017 in Alzheimer’s disease.
• Our in-depth analysis of the forecasted sales data of ATH-1017 from 2028 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ATH-1017 in Alzheimer’s disease. 

Key Questions

• What is the product type, route of administration and mechanism of action of ATH-1017?
• What is the clinical trial status of the study related to ATH-1017 in Alzheimer’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ATH-1017 development?
• What are the key designations that have been granted to ATH-1017 for Alzheimer’s disease?
• What is the forecasted market scenario of ATH-1017 for Alzheimer’s disease?
• What are the forecasted sales of ATH-1017 in Japan?  
• What are the other emerging products available and how are these giving competition to ATH-1017 for Alzheimer’s disease?
• Which are the late-stage emerging therapies under development for the treatment of Alzheimer’s disease?